文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非小细胞肺癌肿瘤、肿瘤边缘、相邻和远处肺组织中 T 细胞 repertoire 的空间异质性。

Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.

机构信息

Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China.

Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.

出版信息

Oncoimmunology. 2023 Oct 20;12(1):2233399. doi: 10.1080/2162402X.2023.2233399. eCollection 2023.


DOI:10.1080/2162402X.2023.2233399
PMID:37876834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10591778/
Abstract

BACKGROUND: A better understanding of T cells in lung cancer and their distribution across tumor-adjacent lungs and peripheral blood is needed to improve efficacy and minimize toxicity from immunotherapy to lung cancer patients. METHODS: Here, we performed CDR3β TCR sequencing of 136 samples from 20 patients with early-stage NSCLC including peripheral blood mononuclear cells, tumors, tumor edges (<1 cm from tumor), as well as adjacent lungs 1 cm, 2 cm, 5 cm, and 10 cm away from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in patients with NSCLC. PD-L1, CD4, and CD8 expression was assessed using immunohistochemical staining, and genomic features were derived by targeted sequencing of 1,021 cancer-related genes. Multiplex immunohistochemistry against PD-1, CTLA4, LAG3, and TIM3 was performed on four patients to assess T cell exhaustion. RESULTS: Our study reveals a decreasing gradient in TIL Tumor Infiltrating Lymphocytes homology with tumor edge, adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression. CONCLUSIONS: Exclusion in T exhaustion cells at play across the lungs of patients with NSCLC may potentially be the mechanism for lung cancer occurrence.

摘要

背景:为了提高免疫疗法治疗肺癌患者的疗效并最大程度降低毒性,需要更好地了解肺癌中的 T 细胞及其在肿瘤相邻肺组织和外周血中的分布情况。

方法:本研究对 20 名早期非小细胞肺癌患者的 136 个样本进行了 CDR3βTCR 测序,包括外周血单核细胞、肿瘤、肿瘤边缘(距离肿瘤<1cm)以及距离肿瘤 1cm、2cm、5cm 和 10cm 的相邻肺组织,以深入了解非小细胞肺癌患者肺部 T 细胞的空间异质性。采用免疫组织化学染色评估 PD-L1、CD4 和 CD8 的表达情况,并通过靶向测序 1021 个癌症相关基因获得基因组特征。对 4 名患者进行了针对 PD-1、CTLA4、LAG3 和 TIM3 的多重免疫组化分析,以评估 T 细胞耗竭情况。

结果:我们的研究揭示了 TIL(肿瘤浸润淋巴细胞)与肿瘤边缘、相邻肺组织和外周血之间的同源性呈逐渐降低的梯度,但在相邻肺组织内部没有明显的与距离相关的 T 细胞迁移模式。此外,我们发现高 T 细胞克隆性和 PD-L1 表达区域的病原体特异性 TCR 减少。

结论:在非小细胞肺癌患者的肺部中,T 细胞衰竭细胞的排除可能是肺癌发生的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/a64a754b0021/KONI_A_2233399_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/2b610f485f29/KONI_A_2233399_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/e7323051b006/KONI_A_2233399_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/27cd54af192d/KONI_A_2233399_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/a64a754b0021/KONI_A_2233399_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/2b610f485f29/KONI_A_2233399_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/e7323051b006/KONI_A_2233399_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/27cd54af192d/KONI_A_2233399_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a07b/10591778/a64a754b0021/KONI_A_2233399_F0004_OC.jpg

相似文献

[1]
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.

Oncoimmunology. 2023

[2]
Dynamic changes in PD-L1 expression and CD8 T cell infiltration in non-small cell lung cancer following chemoradiation therapy.

Lung Cancer. 2019-8-1

[3]
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.

Cancer Biol Med. 2020-8-15

[4]
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.

J Egypt Natl Canc Inst. 2018-12

[5]
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.

Front Immunol. 2022

[6]
Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.

Cell Mol Biol Lett. 2022-6-3

[7]
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.

Theranostics. 2021

[8]
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.

Gastroenterology. 2017-6-23

[9]
N-methyladenosine-modified circIGF2BP3 inhibits CD8 T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.

Mol Cancer. 2021-8-20

[10]
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

J Thorac Oncol. 2017-12-18

引用本文的文献

[1]
CD161CD127CD8 T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus.

Oncoimmunology. 2024

本文引用的文献

[1]
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.

Nat Cancer. 2022-1

[2]
A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.

Front Immunol. 2021

[3]
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.

Lung Cancer. 2021-10

[4]
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

Nat Med. 2021-8

[5]
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers.

Sci Adv. 2021-5

[6]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[7]
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Cancer Cell. 2021-2-8

[8]
Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening.

Nat Biotechnol. 2020-10

[9]
Genomic landscape of lung adenocarcinoma in East Asians.

Nat Genet. 2020-2-3

[10]
Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Nat Commun. 2020-1-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索